Close menu




July 6th, 2021 | 11:34 CEST

Bayer, XPhyto Therapeutics, Pfizer: Here comes the blockbuster of the 4th wave

  • Biotechnology
Photo credits: pixabay.com

Hygiene sluices, rapid tests, disinfectants and vaccines - what was more familiar to laboratory staff or doctors a few years ago has become our daily bread since the outbreak of the pandemic. It stands to reason that the new normality would also leave its mark on the stock market. Indeed, the shares of major pharmaceutical companies have already risen. However, there are still newcomers with considerable potential. Growth companies, in particular, could benefit from the hype surrounding hygiene and health.

time to read: 2 minutes | Author: Nico Popp
ISIN: BAYER AG NA O.N. | DE000BAY0017 , XPHYTO THERAPEUTICS | CA98421R1055 , PFIZER INC. DL-_05 | US7170811035

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Bayer: Value - and what else?

    Bayer is anything but a growth company. Nevertheless, the Leverkusen-based Company is currently regarded by many stock market experts as an exciting pick. Why? The Company is the market leader, shines with good figures and has largely shaken off the glyphosate dispute, which has been a burden for many years, at least in its share price. Added to this is a dividend that currently convinces many investors with more than a 5% dividend yield. While Bayer offers no hope of being the next multiplier, a hefty dividend is a good argument, especially for risk-averse investors.

    In addition to its health care offerings, Bayer also operates in the agricultural technology sector, benefiting from rising commodity prices and the improving inflationary environment. The stock is not hot, but it is a solid one. Over a year, the stock has returned more than 20%. There is not so much fantasy in Bayer at the moment, but there is a lot of value.

    XPhyto: Next-generation PCR test comes to Berlin

    On the other hand, the young Canadian Company XPhyto Therapeutics, which does business in Germany and elsewhere, is more on the growth path. XPhyto has developed a method that enables PCR tests to deliver meaningful results within 20-25 minutes. After only a little more time than error-prone antigen tests, XPhyto's solution provides PCR-quality certainty. Airports or hotels, in particular, could take advantage of the offer. Given the upcoming wave of travel, XPhyto's solution could strike a nerve.

    The Company signed an agreement with ten test centers at the end of June and sent the first tests to Berlin. In addition to test kits, XPhyto offers solutions to help the human body better absorb medical agents, such as patches and solutions, and is developing drugs. In addition to a neurological drug, the Canadians are also working with psychedelic agents. The stock has been on a dive for weeks. While this may not attract investors at first glance, XPhyto Therapeutics offers an exciting product mix. The PCR tests could become a bread-and-butter business in a quarter-wave, and the activities around psychoactive compounds spark the imagination. Investors can bookmark XPhyto - the list of potential catalysts for a turnaround is long.

    Pfizer: What can the Corona profiteer do?

    While fantasy lurks in XPhyto, Pfizer's stock is an open book: the Company is one of the largest pharmaceutical companies in the world, making a name for itself primarily with several blockbuster drugs, each of which generates more than USD 1 billion in annual sales. Pfizer also benefits from its collaboration with BioNTech on the Covid-19 vaccine. Still, the stock has not really gotten off the ground in the past year - the price tags show a yield of just 9%. In addition, there is a dividend of around 3.5% measured against the current share price. The Pfizer share will no longer be a high-flyer but can be a solid foundation in a conservative portfolio.


    Nevertheless, for private investors especially, it can make sense to invest a little more speculatively in the pharmaceutical, laboratory diagnostics, and biotech sectors. While relevant returns on Pfizer and Bayer can only be achieved with large position sizes, courageous speculators can profit with small investments in XPhyto Therapeutics. The rapid PCR test with results from 20 minutes could become the blockbuster of the fourth wave. Given a market capitalization of less than EUR 100 million, the share price is likely to react more clearly to such a development than it would to a big player like Pfizer and Co.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.

    Read

    Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

    MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

    • Biotechnology
    • Pharma

    The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?

    Read

    Commented by Armin Schulz on February 12th, 2024 | 07:00 CET

    MorphoSys, Defence Therapeutics, Bayer - Biotech and Pharma suddenly back in focus

    • Biotechnology
    • Pharma

    Biotech ETFs have been on the rise since the end of October 2023. German biotech companies were able to raise more funds again last year. There are increasing signs that the tough times for investors in biotech and pharmaceutical companies are over. There is also growing activity on the takeover side. Most recently, the takeover bid from Novartis shifted the focus to companies in the healthcare sector. The Swiss pharmaceutical company wants to acquire MorphoSys for EUR 2.7 billion and thus fill up its oncology pipeline. We have selected three companies from the biotech and pharma sectors and examined their current situation.

    Read